CASE STUDY
3-5 pages
Ending HIV: Sangamo Biosciences and Gene Editing
1. What were the pros and cons of Sangamo pursuing its gene editing programs alone versus working with a partner?
2. Does the HIV program offer any special opportunities or challenges?
3. What do you think Sangamo should do regarding the HIV program? (Should it license the technology to a large pharmaceutical? Should it form a joint venture with another biotech or pharma company? If so, who?) (The answer to this question should be a full page.)